Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140683 | 0.80 | P2RX7 (0.42) | FGFR1FGFR4SRCP2RX7HDAC6 | |
| SCHEMBL4123842 | 0.78 | ADORA2A (0.59) | ADORA2AKDM4ELMNA | |
| SCHEMBL13811638 | 0.78 | SRC (0.47) | SRCADORA2AKDM4ELMNA | |
| SCHEMBL4864331 | 0.78 | ADORA2A (0.59) | ADORA2AKDM4ELMNA | |
| SCHEMBL9192712 | 0.78 | SRC (0.44) | FGFR1FGFR4SRCP2RX7ADORA2A | |
| SCHEMBL29729351 | 0.78 | ADORA2A (0.59) | ADORA2AKDM4ELMNA | |
| SCHEMBL6288387 | 0.77 | NPC1 (0.52) | FGFR1FGFR4FDPSP2RX7HDAC6 | |
| SCHEMBL4137935 | 0.75 | CDK1 (0.38) | FGFR1FGFR4SRCP2RX7 | |
| SCHEMBL4120821 | 0.74 | YTHDC1 (0.60) | SRCADORA2APDE4APDE4BPDE4C | |
| SCHEMBL22080198 | 0.74 | FLT4 (0.46) | SRCADORA2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1940843-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007021937-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021937-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | FGFR1 1438/4885FGFR4 1138/4885FDPS 43/4885 |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | FGFR1 1438/4885FGFR4 1138/4885FDPS 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.